TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Post Admission Cognitive Therapy (PACT) for the Inpatient Treatment of Military Personnel With Suicidal Behaviors: A Multi-Site Randomized Controlled Trial
Brief Summary: This study will implement and empirically evaluate the efficacy of a cognitive behavioral intervention program, titled, Post Admission Cognitive Therapy(PACT), for military service members and beneficiaries \[with Veterans expected to be added\] admitted for inpatient care due to severe suicide ideation and/or a recent suicide attempt.


Options:
A: Arm Label: Prevention Program; Type: EXPERIMENTAL; Interventions: Behavioral: Prevention program | Arm Label: Assessment Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prevention program; Assigned to Arm(s): Prevention Program
B: Arm Label: Post Admission Cognitive Therapy (PACT); Type: EXPERIMENTAL; Interventions: Behavioral: Post Admission Cognitive Therapy (PACT) | Arm Label: Enhanced Usual Care (EUC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Post Admission Cognitive Therapy (PACT); Assigned to Arm(s): Post Admission Cognitive Therapy (PACT)
C: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Other: Other | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Other; Assigned to Arm(s): Experimental Arm
D: Arm Label: therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioural therapy | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Intervention Type: BEHAVIORAL; Name: Cognitive behavioural therapy; Assigned to Arm(s): therapy | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Albumin Administration in Septic Cirrhotic Patients With Child > 8 Unrelated to Spontaneous Bacterial Peritonitis on Renal Function and Survival: A Multicenter Randomized Controlled Trial Comparing Use and Non-use of Human Albumin (Vialebex ®)
Brief Summary: Patients with cirrhosis present an increased susceptibility to bacterial infections. Spontaneous bacterial peritonitis (SBP) is the most frequent infection and induces severe circulatory dysfunction associated with renal failure in about 30% of cases. Renal failure is a reliable surrogate marker of in-hospital mortality in patients with SBP or with non-SBP infections. Albumin, as an adjuvant to antibiotherapy reduces significantly the rate of renal failure, in-hospital mortality, and overall mortality (Sort P, et al. NEJM 1999). However, little is known regarding the effect of albumin administration in patients with non-SBP infections. Two recent prospective studies demonstrated that non-SBP infections are associated with impairment of the effective circulating volume and precipitate renal failure whatever the presence of ascites.

The aim of this randomized clinical trial is to evaluate the effects of albumin, associated with appropriate antibiotic therapy, on occurrence or deterioration of renal failure and survival in septic (SIRS criteria required) cirrhotic patients with non-SBP infections and presenting with a Child-Pugh score \> 8.


Options:
A: Arm Label: Standard medical treatment plus albumin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diuretics plus human albumin | Arm Label: Standard medical treatment; Type: OTHER; Interventions: Drug: Diuretics (standard medical treatment) | Intervention Type: DRUG; Name: Diuretics plus human albumin; Assigned to Arm(s): Standard medical treatment plus albumin | Intervention Type: DRUG; Name: Diuretics (standard medical treatment); Assigned to Arm(s): Standard medical treatment
B: Intervention Type: DRUG; Name: albumin 4 gr/L ascites removed; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: albumin 8 gr/L ascites removed; Assigned to Arm(s): N/A
C: Arm Label: Usual treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Human Albumin; Type: EXPERIMENTAL; Interventions: Drug: Human Albumin | Intervention Type: DRUG; Name: Human Albumin; Assigned to Arm(s): Human Albumin
D: Arm Label: HES 130/0.4; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxyethyl starch 130/0.4 | Arm Label: Ringer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringers acetate | Intervention Type: DRUG; Name: 6% Hydroxyethyl starch 130/0.4; Assigned to Arm(s): HES 130/0.4 | Intervention Type: DRUG; Name: Ringers acetate; Assigned to Arm(s): Ringer acetate

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage - A Randomised Clinically Controlled Trial
Brief Summary: Severe maternal bleeding is a serious complication of birth and causes 125.000 deaths worldwide each year. The investigators aim to investigate if early treatment with fibrinogen concentrate versus saline can reduce the incidence of blood transfusion in women with postpartum haemorrhage.

A low level of fibrinogen has been associated with increased blood loss and transfusion requirements in different clinical settings including obstetrical bleeding. Early up-front treatment with fibrinogen may reduce incidence of transfusion by securing optimal haemostatic capacity in women with postpartum haemorrhage.

The investigators plan to enrol 245 patients on four hospitals in the Capital Region of Denmark during a two year period.

As safety measure the investigators plan to use TEG®/Functional Fibrinogen/Rapid-TEG as haemostatic monitoring of all participants during the trial: Baseline test is taken at inclusion before administration of fibrinogen concentrate/placebo. Further tests are taken immediately after intervention, 4 hours and 24 hours after. Baseline test is blinded to the providers of treatment - the rest is clinically available.


Options:
A: Arm Label: Fibrinogen Concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen Concentrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic Saline | Intervention Type: DRUG; Name: Fibrinogen Concentrate; Assigned to Arm(s): Fibrinogen Concentrate | Intervention Type: DRUG; Name: Isotonic Saline; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, Placebo
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage - A Randomised Clinically Controlled Trial
Brief Summary: Severe maternal bleeding is a serious complication of birth and causes 125.000 deaths worldwide each year. The investigators aim to investigate if early treatment with fibrinogen concentrate versus saline can reduce the incidence of blood transfusion in women with postpartum haemorrhage.

A low level of fibrinogen has been associated with increased blood loss and transfusion requirements in different clinical settings including obstetrical bleeding. Early up-front treatment with fibrinogen may reduce incidence of transfusion by securing optimal haemostatic capacity in women with postpartum haemorrhage.

The investigators plan to enrol 245 patients on four hospitals in the Capital Region of Denmark during a two year period.

As safety measure the investigators plan to use TEG®/Functional Fibrinogen/Rapid-TEG as haemostatic monitoring of all participants during the trial: Baseline test is taken at inclusion before administration of fibrinogen concentrate/placebo. Further tests are taken immediately after intervention, 4 hours and 24 hours after. Baseline test is blinded to the providers of treatment - the rest is clinically available.


Options:
A: Arm Label: Saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline solution | Arm Label: Fibrinogen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fibrinogen | Arm Label: Prothrombin complex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prothrombin complex | Intervention Type: DRUG; Name: Fibrinogen; Assigned to Arm(s): Fibrinogen | Intervention Type: DRUG; Name: Saline solution; Assigned to Arm(s): Saline solution | Intervention Type: DRUG; Name: Prothrombin complex; Assigned to Arm(s): Prothrombin complex
B: Arm Label: Fibrinogen Concentrate (Human); Type: EXPERIMENTAL; Interventions: Biological: Fibrinogen Concentrate (Human) (FCH) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Fibrinogen Concentrate (Human) (FCH); Assigned to Arm(s): Fibrinogen Concentrate (Human) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Fibrinogen Concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen Concentrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic Saline | Intervention Type: DRUG; Name: Fibrinogen Concentrate; Assigned to Arm(s): Fibrinogen Concentrate | Intervention Type: DRUG; Name: Isotonic Saline; Assigned to Arm(s): Placebo
D: Arm Label: Fibrinogen if FibTEM < 8 mm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Human fibrinogen concentrate | Arm Label: Fibrinogen if FibTEM < 13 mm; Type: EXPERIMENTAL; Interventions: Drug: Human fibrinogen concentrate | Intervention Type: DRUG; Name: Human fibrinogen concentrate; Assigned to Arm(s): Fibrinogen if FibTEM < 13 mm, Fibrinogen if FibTEM < 8 mm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage - A Randomised Clinically Controlled Trial
Brief Summary: Severe maternal bleeding is a serious complication of birth and causes 125.000 deaths worldwide each year. The investigators aim to investigate if early treatment with fibrinogen concentrate versus saline can reduce the incidence of blood transfusion in women with postpartum haemorrhage.

A low level of fibrinogen has been associated with increased blood loss and transfusion requirements in different clinical settings including obstetrical bleeding. Early up-front treatment with fibrinogen may reduce incidence of transfusion by securing optimal haemostatic capacity in women with postpartum haemorrhage.

The investigators plan to enrol 245 patients on four hospitals in the Capital Region of Denmark during a two year period.

As safety measure the investigators plan to use TEG®/Functional Fibrinogen/Rapid-TEG as haemostatic monitoring of all participants during the trial: Baseline test is taken at inclusion before administration of fibrinogen concentrate/placebo. Further tests are taken immediately after intervention, 4 hours and 24 hours after. Baseline test is blinded to the providers of treatment - the rest is clinically available.


Options:
A: Arm Label: Fibrinogen Concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen Concentrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic Saline | Intervention Type: DRUG; Name: Fibrinogen Concentrate; Assigned to Arm(s): Fibrinogen Concentrate | Intervention Type: DRUG; Name: Isotonic Saline; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
C: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo [Saline] | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo [Saline]; Assigned to Arm(s): placebo
D: Arm Label: Standard care for post-partum hemorrhage; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Care | Arm Label: rFVIIa; Type: EXPERIMENTAL; Interventions: Drug: rFVIIa | Intervention Type: DRUG; Name: rFVIIa; Assigned to Arm(s): rFVIIa | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): Standard care for post-partum hemorrhage

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study
Brief Summary: This study evaluated two chemotherapy regimens with and without the addition of interferon in patients with advanced or recurrent melanoma.


Options:
A: Arm Label: Arm A consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab - Arm A | Arm Label: Arm B consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab + Ipilimumab - Arm B | Intervention Type: DRUG; Name: Nivolumab - Arm A; Assigned to Arm(s): Arm A consists of 3 phases or steps | Intervention Type: DRUG; Name: Nivolumab + Ipilimumab - Arm B; Assigned to Arm(s): Arm B consists of 3 phases or steps
B: Arm Label: Temozolomide (TMZ); Type: EXPERIMENTAL; Interventions: Drug: Temozolomide (TMZ) | Arm Label: Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI); Type: EXPERIMENTAL; Interventions: Drug: Temozolomide (TMZ), Drug: Pegylated Interferon Alpha-2b (PGI) | Intervention Type: DRUG; Name: Temozolomide (TMZ); Assigned to Arm(s): Temozolomide (TMZ), Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI) | Intervention Type: DRUG; Name: Pegylated Interferon Alpha-2b (PGI); Assigned to Arm(s): Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Elesclomol (STA-4783) | Arm Label: 2; Type: OTHER; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: Elesclomol (STA-4783); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
D: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Dacarbazine, Drug: Fotemustine | Arm Label: A2; Type: EXPERIMENTAL; Interventions: Drug: Dacarbazine, Drug: Fotemustine, Drug: Interferon Alfa-2b | Arm Label: B1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Arm Label: B2; Type: EXPERIMENTAL; Interventions: Drug: Dacarbazine, Drug: Interferon Alfa-2b | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): A1, A2, B1, B2 | Intervention Type: DRUG; Name: Fotemustine; Assigned to Arm(s): A1, A2 | Intervention Type: DRUG; Name: Interferon Alfa-2b; Assigned to Arm(s): A2, B2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy Safety, and Patient Use (User Study) of Symbicort® (Budesonide/Formoterol) Breath Actuated Metered Dose Inhaler (BA MDI) 2x160/4.5 μg Twice Daily Compared With Symbicort (Budesonide/Formoterol) AC (Actuation Counter) pMDI® 2x160/4.5 μg Twice Daily and Budesonide AC pMDI 2x160 μg Twice Daily in Adult and Adolescent Asthmatics
Brief Summary: This is a comparison of the efficacy of the Symbicort breath actuated dose inhaler to the Symbicort pressured meter dose inhaler after 12 weeks of a twice a day dose.


Options:
A: Intervention Type: DRUG; Name: beclomethasone dipropionate plus formoterol fumarate combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone propionate plus salmeterol xinafoate combination; Assigned to Arm(s): N/A
B: Arm Label: 1 Symbicort/inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort | Arm Label: Symbicort/inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort | Arm Label: Budesonide/inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Intervention Type: DRUG; Name: Symbicort; Assigned to Arm(s): 1 Symbicort/inhaler | Intervention Type: DRUG; Name: Symbicort; Assigned to Arm(s): Symbicort/inhaler | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide/inhaler
C: Arm Label: FF/VI; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate + vilanterol, Drug: inhaled corticosteroid with or without a long acting beta2-agonist | Arm Label: ICS or ICS/LABA maintenance therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: inhaled corticosteroid with or without a long acting beta2-agonist | Intervention Type: DRUG; Name: fluticasone furoate + vilanterol; Assigned to Arm(s): FF/VI | Intervention Type: DRUG; Name: inhaled corticosteroid with or without a long acting beta2-agonist; Assigned to Arm(s): FF/VI, ICS or ICS/LABA maintenance therapy
D: Arm Label: Fixed Combination of Budesonide and formoterol; Type: EXPERIMENTAL; Interventions: Drug: Fixed combination of budesonide and formoterol | Arm Label: Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Intervention Type: DRUG; Name: Fixed combination of budesonide and formoterol; Assigned to Arm(s): Fixed Combination of Budesonide and formoterol | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nifedipine vs. Indomethacin in the Treatment of Preterm Labour and Short Cervix. A Randomized, Controlled Trial.
Brief Summary: The purpose of this study was to compare the effectiveness of nifedipine versus indomethacin as tocolytic for the treatment of preterm labour with short cervix (\< 2.5cms).


Options:
A: Arm Label: Atosiban; Type: EXPERIMENTAL; Interventions: Drug: Atosiban | Arm Label: Nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine
B: Arm Label: Magnesium sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium sulfate | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Magnesium sulfate | Intervention Type: DRUG; Name: Magnesium sulfate; Assigned to Arm(s): Magnesium sulfate, Normal saline
C: Arm Label: Magnesium sulphate; Type: EXPERIMENTAL; Interventions: Drug: Magnesium Sulfate | Arm Label: Ritodrine; Type: EXPERIMENTAL; Interventions: Drug: Ritodrine | Arm Label: Calcium channel blocker; Type: EXPERIMENTAL; Interventions: Drug: Calcium Channel Blockers | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): Magnesium sulphate | Intervention Type: DRUG; Name: Ritodrine; Assigned to Arm(s): Ritodrine | Intervention Type: DRUG; Name: Calcium Channel Blockers; Assigned to Arm(s): Calcium channel blocker
D: Arm Label: Nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Nifedipine | Arm Label: Indomethacin; Type: EXPERIMENTAL; Interventions: Drug: Indomethacin | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Variations in Care: Comparing Heart Failure Care Transition Intervention Effects
Brief Summary: The purpose of this study is to compare the effect of implementing wireless remote monitoring combined with structured telephone monitoring, versus current care, on variation in rehospitalization among older patients hospitalized with heart failure at six medical centers.


Options:
A: Arm Label: Control group (Group A); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Intervention group (Group B); Type: OTHER; Interventions: Other: Home-based telehealth program, Other: Home-based rehabilitation, Other: Usual care | Intervention Type: OTHER; Name: Home-based telehealth program; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Home-based rehabilitation; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control group (Group A), Intervention group (Group B)
B: Arm Label: Current Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Care Transition Intervention; Type: EXPERIMENTAL; Interventions: Other: Structured Telephone / Remote Outpatient Monitoring | Intervention Type: OTHER; Name: Structured Telephone / Remote Outpatient Monitoring; Assigned to Arm(s): Care Transition Intervention
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Behavioral: Health coaching | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): Usual Care
D: Arm Label: telerehabilitation group; Type: EXPERIMENTAL; Interventions: Other: home-based telerehabilitation | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: home-based telerehabilitation; Assigned to Arm(s): telerehabilitation group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Variations in Care: Comparing Heart Failure Care Transition Intervention Effects
Brief Summary: The purpose of this study is to compare the effect of implementing wireless remote monitoring combined with structured telephone monitoring, versus current care, on variation in rehospitalization among older patients hospitalized with heart failure at six medical centers.


Options:
A: Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: educational material | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: educational material; Assigned to Arm(s): Intervention group
B: Arm Label: Current Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Care Transition Intervention; Type: EXPERIMENTAL; Interventions: Other: Structured Telephone / Remote Outpatient Monitoring | Intervention Type: OTHER; Name: Structured Telephone / Remote Outpatient Monitoring; Assigned to Arm(s): Care Transition Intervention
C: Arm Label: Hip Hop Stroke educational program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hip Hop Stroke educational program | Arm Label: Nutrition Education program; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Nutrition Education program | Intervention Type: BEHAVIORAL; Name: Hip Hop Stroke educational program; Assigned to Arm(s): Hip Hop Stroke educational program | Intervention Type: BEHAVIORAL; Name: Nutrition Education program; Assigned to Arm(s): Nutrition Education program
D: Arm Label: Activity-Self Management; Type: EXPERIMENTAL; Interventions: Behavioral: Self-Management and Motivational Interviewing | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-Management and Motivational Interviewing; Assigned to Arm(s): Activity-Self Management

Answer: B